HomeCompareNPPNY vs JNJ

NPPNY vs JNJ: Dividend Comparison 2026

NPPNY yields 2.84% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPPNY wins by $128.0K in total portfolio value
10 years
NPPNY
NPPNY
● Live price
2.84%
Share price
$7.40
Annual div
$0.21
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$158.3K
Annual income
$65,881.22
Full NPPNY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NPPNY vs JNJ

📍 NPPNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPPNYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPPNY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPPNY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPPNY
Annual income on $10K today (after 15% tax)
$241.22/yr
After 10yr DRIP, annual income (after tax)
$55,999.04/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NPPNY beats the other by $52,013.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPPNY + JNJ for your $10,000?

NPPNY: 50%JNJ: 50%
100% JNJ50/50100% NPPNY
Portfolio after 10yr
$94.3K
Annual income
$35,285.31/yr
Blended yield
37.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NPPNY
No analyst data
Altman Z
6.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPPNY buys
0
JNJ buys
0
No recent congressional trades found for NPPNY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPPNYJNJ
Forward yield2.84%2.13%
Annual dividend / share$0.21$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%28%
Portfolio after 10y$158.3K$30.3K
Annual income after 10y$65,881.22$4,689.40
Total dividends collected$128.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPPNY vs JNJ ($10,000, DRIP)

YearNPPNY PortfolioNPPNY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,119$419.15$10,592$272.30+$527.00NPPNY
2$12,541$643.33$11,289$357.73+$1.3KNPPNY
3$14,420$1,001.58$12,123$472.89+$2.3KNPPNY
4$17,019$1,589.76$13,141$629.86+$3.9KNPPNY
5$20,801$2,590.00$14,408$846.81+$6.4KNPPNY
6$26,626$4,369.50$16,021$1,151.60+$10.6KNPPNY
7$36,211$7,720.76$18,122$1,588.22+$18.1KNPPNY
8$53,240$14,493.90$20,930$2,228.20+$32.3KNPPNY
9$86,382$29,415.55$24,792$3,191.91+$61.6KNPPNY
10$158,310$65,881.22$30,274$4,689.40+$128.0KNPPNY

NPPNY vs JNJ: Complete Analysis 2026

NPPNYStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPPNY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NPPNY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPPNY vs SCHDNPPNY vs JEPINPPNY vs ONPPNY vs KONPPNY vs MAINNPPNY vs ABBVNPPNY vs MRKNPPNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.